| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | MAIA Biotechnology, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| Do | MAIA Biotechnology, Inc.: MAIA Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer | 108 | GlobeNewswire (Europe) | Outstanding measure of efficacy relative to high-risk cancers with limited treatment options CHICAGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the... ► Artikel lesen | |
| 14.10. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.10. | MAIA Biotechnology announces $0.74M private placement | 2 | Seeking Alpha | ||
| MAIA BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 13.10. | MAIA Biotechnology raises $736,600 in private placement | 1 | Investing.com | ||
| 13.10. | MAIA Biotechnology sichert sich 736.600 US-Dollar durch Privatplatzierung | 1 | Investing.com Deutsch | ||
| 13.10. | MAIA Biotechnology, Inc.: MAIA Biotechnology Announces $736,600 Private Placement | 1 | GlobeNewswire (USA) | ||
| 07.10. | MAIA Biotechnology to hold up to 90% of liquid assets in crypto | 1 | Seeking Alpha | ||
| 07.10. | MAIA Biotechnology adopts crypto treasury strategy; shares up | 1 | Seeking Alpha | ||
| 07.10. | MAIA Biotechnology, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.10. | MAIA Biotechnology, Inc.: MAIA Biotechnology to Initiate Digital Asset Treasury Strategy Focused on Top-Tier Crypto Assets | 121 | GlobeNewswire (Europe) | MAIA's Board of Directors authorizes holdings of up to 90% of the Company's liquid assets in cryptocurrencies (BTC), Ethereum (ETH), and USD Coin (USDC) CHICAGO, Oct. 07, 2025 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| 30.09. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.09. | MAIA Biotechnology announces $2.25 million private placement | 2 | Seeking Alpha | ||
| 29.09. | MAIA Biotechnology, Inc.: MAIA Biotechnology Announces $2.25 Million Private Placement | 3 | GlobeNewswire (USA) | ||
| 24.09. | MAIA Biotechnology awarded $2.3 million grant by NIH | 1 | Seeking Alpha | ||
| 24.09. | MAIA Biotechnology, Inc.: MAIA Biotechnology Awarded $2.3 Million Grant by National Institutes of Health for THIO-101 Phase 2 Trial of Cancer-Fighting Agent | 119 | GlobeNewswire (Europe) | THIO-101 Phase 2 trial to enroll patients in the U.S. as part of the expansion of the study in third-line treatment for advanced non-small cell lung cancer (NSCLC) CHICAGO, Sept. 24, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 18.09. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.09. | MAIA Biotechnology, Inc.: MAIA Biotechnology Highlights Positive Efficacy Data from THIO-101 Phase 2 Clinical Trial in Non-Small Cell Lung Cancer | 158 | GlobeNewswire (Europe) | CHICAGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies... ► Artikel lesen | |
| 08.09. | Maia Biotechnology stellt Phase-2-Studiendaten zu Lungenkrebsmedikament vor | 2 | Investing.com Deutsch | ||
| 08.09. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 102,90 | -1,00 % | Gilead Sciences: Ausbruch mit Ansage! | Die Aktie von Gilead Sciences zählt zu den besten Performern im Pharmasektor und überzeugt mit stabiler Ertragskraft, technischem Aufwärtstrend und positiver Analystenstimmung. Wir hatten vergangenen... ► Artikel lesen | |
| ABBVIE | 197,20 | +0,31 % | AbbVie erzielt positive Studienergebnisse mit RINVOQ bei rheumatoider Arthritis | Der US-Pharmakonzern AbbVie hat in einer späten klinischen Studie positive Ergebnisse für seinen Wirkstoff Upadacitinib (Handelsname RINVOQ) erzielt. In der Phase-3b/4-Studie SELECT-SWITCH wurde das... ► Artikel lesen | |
| ABBOTT LABORATORIES | 108,74 | -0,02 % | A Look Into Abbott Laboratories Inc's Price Over Earnings | ||
| EDWARDS LIFESCIENCES | 65,82 | -0,12 % | Piper Sandler Maintains Overweight on Edwards Lifesciences (EW) Ahead of PARTNER 3 7-Year Results | ||
| SCHOTT PHARMA | 20,250 | +0,75 % | EQS-AFR: SCHOTT Pharma AG & Co. KGaA: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: SCHOTT Pharma AG & Co. KGaA
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
SCHOTT Pharma AG & Co. KGaA:... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 24,900 | +5,06 % | Assembly Biosciences nach +279% in 6 Monaten: Was ist noch drin? | Mein Top-Favorit 2025 hat mit beeindruckender Stärke ein neues Langzeithoch markiert: Aktien von Assembly Biosciences kosten mittlerweile fast 30 US$, nachdem sie im April noch für 7,75 US$ zu haben... ► Artikel lesen | |
| PENTIXAPHARM | 1,570 | -0,38 % | EQS-Adhoc: Pentixapharm Holding AG: Pentixapharm fokussiert Entwicklung auf fortgeschrittene klinische Programme und stärkt finanzielle Position durch Einstellung präklinischer Aktivitäten | EQS-Ad-hoc: Pentixapharm Holding AG / Schlagwort(e): Strategische Unternehmensentscheidung
Pentixapharm Holding AG: Pentixapharm fokussiert Entwicklung auf fortgeschrittene klinische Programme... ► Artikel lesen | |
| CASSAVA SCIENCES | 3,167 | -5,80 % | CASSAVA SCIENCES INC - 8-K, Current Report | ||
| AXSOME THERAPEUTICS | 111,35 | +1,78 % | Axsome Therapeutics, Inc.: Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | Total 2Q 2025 net product revenue of $150.0 million, representing growth of 72% year-over-year and 24% sequentially AUVELITY® 2Q 2025 net product sales of $119.6 million, representing growth of... ► Artikel lesen | |
| ZEALAND PHARMA | 61,94 | -0,58 % | Zealand Pharma major shareholder announcement: Van Herk Investments B.V. | ||
| MEDPACE | 513,80 | -0,04 % | Biotech Earnings Watch: BSX, MEDP, MOH, TMO Set To Report Oct 22 | WASHINGTON (dpa-AFX) - With earnings season in full swing, investors are turning their attention to a quartet of healthcare and biotech names, BSX, MEDP, MOH, and TMO, set to report Q3 results... ► Artikel lesen | |
| UNITED THERAPEUTICS | 365,50 | -0,33 % | If You Invested $100 In United Therapeutics Stock 15 Years Ago, You Would Have This Much Today | ||
| UCB | 247,10 | 0,00 % | UCB Announces Promising Study Results For Investigational TK2 Deficiency Therapy | BRUSSELS (dpa-AFX) - According to results from a multicenter study published by Neurology, UCB SA (UCBJY) showed on Monday, that its investigational pyrimidine nucleoside therapy has the potential... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 363,80 | -0,38 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals to Release Third-Quarter 2025 Financial Results and Host Webcast on November 4, 2025 | ||
| BRIDGEBIO PHARMA | 46,340 | +0,02 % | BridgeBio Pharma stock rating reiterated as Overweight by Wells Fargo |